VanEck Associates’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$403K Buy
22,614
+230
+1% +$4.1K ﹤0.01% 1183
2025
Q1
$399K Buy
22,384
+1,325
+6% +$23.6K ﹤0.01% 1170
2024
Q4
$628K Sell
21,059
-3,185
-13% -$95K ﹤0.01% 1108
2024
Q3
$392K Buy
24,244
+376
+2% +$6.08K ﹤0.01% 1117
2024
Q2
$409K Buy
23,868
+8,094
+51% +$139K ﹤0.01% 1112
2024
Q1
$247K Buy
15,774
+706
+5% +$11.1K ﹤0.01% 1150
2023
Q4
$225K Sell
15,068
-5
-0% -$75 ﹤0.01% 1154
2023
Q3
$243K Buy
15,073
+959
+7% +$15.5K ﹤0.01% 1129
2023
Q2
$586K Sell
14,114
-2,037
-13% -$84.6K ﹤0.01% 1004
2023
Q1
$971K Sell
16,151
-226
-1% -$13.6K ﹤0.01% 841
2022
Q4
$1.2M Buy
16,377
+2,845
+21% +$209K ﹤0.01% 770
2022
Q3
$1.03M Buy
13,532
+46
+0.3% +$3.5K ﹤0.01% 763
2022
Q2
$937K Sell
13,486
-4,661
-26% -$324K ﹤0.01% 802
2022
Q1
$1.5M Buy
18,147
+101
+0.6% +$8.37K ﹤0.01% 762
2021
Q4
$1.36M Sell
18,046
-1,059
-6% -$79.5K ﹤0.01% 792
2021
Q3
$2.22M Sell
19,105
-1,533
-7% -$178K 0.01% 652
2021
Q2
$4.58M Buy
20,638
+1,555
+8% +$345K 0.01% 479
2021
Q1
$2.52M Buy
19,083
+281
+1% +$37.1K 0.01% 559
2020
Q4
$3.25M Sell
18,802
-9,912
-35% -$1.71M 0.01% 456
2020
Q3
$3.2M Buy
28,714
+598
+2% +$66.6K 0.01% 399
2020
Q2
$1.67M Buy
28,116
+243
+0.9% +$14.4K 0.01% 518
2020
Q1
$1.88M Buy
27,873
+953
+4% +$64.2K 0.01% 465
2019
Q4
$2.27M Buy
26,920
+830
+3% +$70K 0.01% 500
2019
Q3
$1.95M Buy
26,090
+88
+0.3% +$6.58K 0.01% 481
2019
Q2
$1.64M Buy
26,002
+3,111
+14% +$197K 0.01% 494
2019
Q1
$1.1M Buy
22,891
+532
+2% +$25.6K 0.01% 561
2018
Q4
$749K Buy
22,359
+3,345
+18% +$112K ﹤0.01% 586
2018
Q3
$996K Buy
19,014
+1,089
+6% +$57K ﹤0.01% 556
2018
Q2
$561K Sell
17,925
-1,227
-6% -$38.4K ﹤0.01% 661
2018
Q1
$418K Buy
19,152
+1,278
+7% +$27.9K ﹤0.01% 587
2017
Q4
$361K Sell
17,874
-1,350
-7% -$27.3K ﹤0.01% 593
2017
Q3
$382K Buy
19,224
+858
+5% +$17K ﹤0.01% 590
2017
Q2
$318K Buy
+18,366
New +$318K ﹤0.01% 605